Aetiology and resistance patterns of community-acquired pneumonia in León, Nicaragua

International Journal of Antimicrobial Agents

Volumn 28, Issue 5, 2006, Pages 423-427

  Matute, A J ^a   Brouwer, W P ^b   Hak, E ^b   Delgado, E ^a   Alonso, E ^a   Hoepelman, I M ^b  

^a Universidad Nacional Autónoma de Nicaragua   (Nicaragua)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Aetiology; Antibiotics; Community acquired pneumonia; Resistance

Indexed keywords

ERYTHROMYCIN; PENICILLIN G;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY ACQUIRED PNEUMONIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOPLASMA PNEUMONIA; NICARAGUA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY-ACQUIRED INFECTIONS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOPLASMA PNEUMONIAE; NICARAGUA; OXACILLIN; PENICILLINS; PNEUMONIA, BACTERIAL; PREVALENCE; PSEUDOMONAS AERUGINOSA; SPUTUM; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 33750309695     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.07.016     Document Type: Article

References (22)

1. Kalin M., Ortvist A., Almela M., et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 182 (2000) 840-847
2. Fry A.M., Shay D.K., Holman R., Curns A.T., and Anderson L.J. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 294 (2005) 2712-2719
3. Oosterheert J.J., Bonten M.J., Hak E., Lammer J.W., Schneider M.M., and Hoepelman I.M. The increase in pneumonia-related morbidity and mortality among adults in the Netherlands and possible explanations for it. Ned Tijdsch NTvG 148 (2004) 1765-1769 [in Dutch]
4. Scott J.A., Hall A.J., Muyodi C., et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet 355 (2000) 1225-1230
5. Ruiz-Gonzalez A., Falguera M., Nogues A., and Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown aetiology? A microbiological study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 106 (1999) 385-390
6. Marston B.J., Plouffe J.F., File Jr. T.M., et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 157 (1997) 1709-1718
7. Tan T.Q. Antibiotic resistant infections due to Streptococcus pneumoniae: impact on therapeutic options and clinical outcome. Curr Opin Infect Dis 16 (2003) 271-277
8. Loeb M. Pneumonia in older persons. Clin Infect Dis 37 (2003) 1335-1339
9. Song J.H., Lee N.Y., Ichiyama S., et al. Spread of drug-resistant Streptococcus pneumoniae in Asian countries. Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clin Infect Dis 28 (1999) 1206-1211
10. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy 50 Suppl. 1 (2004) 3-10
11. Schouten J.A., Prins J.M., Bonten M.J., et al. Revised SWAB guidelines for antimicrobial therapy of community-acquired pneumonia. Neth J Med 63 (2005) 323-335
12. Matute A.J., Hak E., Schurink C.A., et al. Resistance of uropathogens in symptomatic urinary tract infections in Leon, Nicaragua. Int J Antimicrob Agents 23 (2004) 506-509
13. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care Med 2001;163:1730-54.
14. Murray P.R., and Washington II J.A. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin Proc 50 (1975) 339-344
15. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Supplement M100-S11. Wayne, PA: NCCLS; 2001.
16. Jacobs E. Serological diagnosis of Mycoplasma pneumoniae infections: a critical review of current procedures. Clin Infect Dis 17 Suppl. 1 (1993) S79-S82
17. Stout JE, Yu VL. Legionellosis. N Engl J Med 1997;337:682-7.
18. Ruiz M., Ewig S., Torres A., et al. Severe community-acquired pneumonia: risk factors and follow-up epidemiology. Am J Respir Crit Care Med 160 (1999) 923-929
19. Jardim J.R., Rico G., de la Roza C., et al. A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial. Arch Bronconeumol 39 (2003) 387-393
20. Hortal M., Ruvinsky R., Rossi A., et al. Impact of Streptococcus pneumoniae on pneumonia in Latin American children. SIREVA-Vigia Group. Rev Panam Salud Publica 8 (2000) 185-195 [in Spanish]
21. Bohte R., Hermans J., and van den Broek P.J. Early recognition of Streptococcus pneumoniae in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 15 (1996) 201-205
22. Aleva RM, Boersma WG; The Dutch Thoracic Society. Guideline. 'Diagnosis and treatment of community-acquired pneumonia' from the Dutch Thoracic Society. Ned Tijdschr Geneeskd 2005;149:2501-7 [in Dutch].